TB006 Alzheimer's Treatment with in The Woodlands, TX
Alzheimer’s disease doesn’t start with memory loss. It starts years earlier — with chronic brain inflammation, a buildup of a protein called galectin-3, and immune cells in the brain that stop protecting neurons and start destroying them. By the time a diagnosis lands, significant damage has already occurred. Standard treatments focus on amyloid plaques or symptom management. They don’t address the inflammatory cascade driving the disease forward.
TB006 takes a different approach. It’s an antibody therapy that targets galectin-3 — a protein directly involved in the brain inflammation that accelerates Alzheimer’s progression (source). At our Woodlands clinic, we offer physician-supervised TB006 protocols as part of a comprehensive neurocognitive program designed to address the inflammatory mechanisms behind cognitive decline.
Schedule your consultation today, or call us at (346) 443-8165 to discuss whether TB006 may be appropriate for your situation.
* TB006 is an investigational therapy that has not been approved by the FDA for the treatment of Alzheimer’s disease or any other condition. All TB006 protocols at our clinic are administered under physician supervision as part of an individualized clinical assessment.
What Is TB006 and How Does It Target Alzheimer's Disease?
TB006 selectively binds to galectin-3 — a protein now recognized as a key driver of brain inflammation in Alzheimer’s disease. Rather than targeting amyloid plaques or tau tangles directly, TB006 goes after the upstream immune dysfunction that research suggests fuels neuronal damage and cognitive decline.
Here’s what happens in an Alzheimer’s brain: microglia — the brain’s resident immune cells — become chronically overactivated. Instead of protecting neurons, they pump out excessive galectin-3, which keeps them locked in an inflammatory state that damages synapses and accelerates cognitive deterioration (source). TB006 binds to that galectin-3 and neutralizes its inflammatory activity. The goal isn’t simply to remove plaques — it’s to address why the brain’s immune system turns destructive in the first place.
This is a fundamentally different strategy than FDA-approved therapies like lecanemab (Leqembi) and donanemab (Kisunla), which focus on clearing amyloid plaques. While those therapies have shown statistically significant but clinically modest effects on cognitive decline in Phase 3 trials (source), brain inflammation has remained largely unaddressed — which is precisely the gap TB006 is designed to fill.
Why Does Galectin-3 Matter in Alzheimer's Disease?
In Alzheimer’s brains, galectin-3 levels are significantly elevated — particularly in immune cells clustered around amyloid plaques. Research from Boza-Serrano et al. found galectin-3 was dramatically increased in the brains of Alzheimer’s patients and in mouse models of the disease, concentrated specifically in the immune cells surrounding plaques (source). When researchers removed galectin-3 from those mouse models, the brain’s inflammatory response quieted down and cognitive function improved.
Galectin-3 triggers a vicious cycle: damaged neurons activate the brain’s immune cells, those immune cells produce more galectin-3, and the excess galectin-3 keeps those cells locked in a chronically inflamed state — creating a self-perpetuating loop of brain inflammation that drives further damage (source). Additional research has shown that galectin-3 causes amyloid proteins to clump together more aggressively, increasing plaque toxicity (source), and several small human studies have linked elevated galectin-3 in blood or spinal fluid to cognitive impairment (source).
By targeting galectin-3 directly, TB006 aims to break this inflammatory cycle at its source rather than managing its downstream effects.
How Is TB006 Different from FDA-Approved Alzheimer's Treatments?
TB006 targets brain inflammation. FDA-approved therapies — lecanemab and donanemab — target amyloid plaques. These are fundamentally different approaches to the same disease.
The Clarity AD trial for lecanemab showed a modest slowing of cognitive decline over 18 months, but also carried notable risks: brain swelling and microbleeds (called ARIA) occurred in 12.6% of treated participants (source). TB006 was not associated with ARIA in clinical studies to date (source) — a meaningful safety distinction, though long-term data in larger populations is still needed.
It’s important to understand what TB006 is not: it is not FDA-approved and has not completed Phase 3 trials. The Phase 1/2 trial narrowly missed its primary measure of cognitive decline at three months, though treated patients showed 63 percent less worsening compared to placebo (source). We present this transparently so you can make informed decisions.
Ready to Take the Next Step?
Schedule your consultation today and take the first step toward better health.
What Does the Current Research Say About TB006?
The research is early-stage but scientifically compelling. Preclinical studies showed that blocking galectin-3 reduces immune overactivation in the brain, lowers inflammation markers, and supports neuron survival in Alzheimer’s models (source). In the Phase 1 healthy volunteer study, single doses up to 5,000 mg were safe and well-tolerated (source).
The Phase 1/2 study in 140 people with mild to severe Alzheimer’s reported no serious treatment-related side effects and no ARIA. A standard cognitive test (MMSE) showed significant improvement after one month. TB006 also reduced a key amyloid marker in the blood, and the company reported amyloid plaque reduction after 30 days on brain imaging (source). The galectin-3 pathway itself has a growing evidence base from multiple independent research groups (source, source, source).
We are transparent with every patient: TB006 is investigational. The evidence is promising but not conclusive.
Who Is a Candidate and What Does Treatment Look Like?
Candidates typically include individuals with early-stage Alzheimer’s, mild cognitive impairment with signs of brain inflammation, or strong family history combined with emerging cognitive concerns. Our evaluation includes cognitive testing, inflammatory blood panels, metabolic assessment, and review of existing workups. Patients with advanced-stage Alzheimer’s, active autoimmune conditions affecting the brain, or certain immune-related contraindications may not be candidates.
TB006 is administered as an IV infusion under direct physician supervision. Each session takes approximately 60–90 minutes including monitoring. Before your first infusion, we establish baseline cognitive and biomarker measurements. Between infusions, follow-up testing lets us measure your response objectively. We integrate TB006 within a broader framework that may include metabolic optimization, inflammatory management, and evidence-based lifestyle interventions.
Side Effects, Cost, and Transparency
The most commonly reported side effects are mild infusion reactions — temporary headache, fatigue, or mild nausea — that typically resolve within hours. Because TB006 affects immune function, we monitor immune and inflammatory markers throughout treatment.
TB006 is not covered by insurance. We provide transparent pricing during consultation, including detailed cost breakdowns before treatment begins. HSA/FSA documentation is available when applicable.
Why Choose TIFAAR in The Woodlands?
We combine access to emerging therapies with medical rigor — physician-supervised protocols, comprehensive cognitive monitoring, and honest communication about what’s investigational and what’s established. We coordinate with your existing neurologists and specialists to ensure TB006 complements your current plan. The Woodlands residents shouldn’t have to travel to Houston medical centers to access emerging Alzheimer’s therapies.
Schedule your consultation today, or call us at (346) 443-8165 to discuss whether TB006 may be appropriate for your situation.
Request an Appointment
- Office Hours
What Our Patients Say
Real stories from real people who’ve transformed their lives with TIFAAR
Ready to Start Your Anti-Aging Journey?
Take the first step toward looking and feeling your best. Schedule your comprehensive consultation today.
Frequently Asked Questions
You've got questions, we've got answers.
Don’t see what you’re looking for?
Is TB006 FDA-approved?
No. TB006 is investigational and has not been approved by the FDA for any condition. We provide complete information about its regulatory status during your consultation.
How is TB006 administered?
As an intravenous infusion at our Woodlands clinic. Each session takes approximately 60–90 minutes including post-infusion monitoring, with frequency determined by your individualized protocol.
Can TB006 be combined with other Alzheimer's medications?
In some cases, yes. We coordinate with your neurologist to evaluate whether combination approaches — including alongside amyloid-targeted treatments — are appropriate for your situation.
How long before I might notice changes?
Biomarker changes may appear within the first treatment course. Cognitive improvements typically require multiple months to show measurable trends. We track response through standardized testing at defined intervals.
Who is not a candidate for TB006?
Patients with advanced-stage Alzheimer’s, active autoimmune conditions affecting the brain, or certain immune-related contraindications. Our evaluation identifies any factors that would make TB006 inadvisable before treatment begins.